Free Trial
→ Read now. Do not delete. You’ve been warned. (From Porter & Company) (Ad)tc pixel Free HBP Stock Alerts

Helix BioPharma (HBP) Competitors

Helix BioPharma logo
C$1.58 0.00 (0.00%)
As of 06/12/2026
Compare

HBP vs. FRX, PLI, ABCN, EMC, and TH

Should you buy Helix BioPharma stock or one of its competitors? MarketBeat compares Helix BioPharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Helix BioPharma include Fennec Pharmaceuticals (FRX), ProMetic Life Sciences (PLI), VIVO Cannabis (ABCN), Emblem (EMC), and Theratechnologies (TH). These companies are all part of the "biotechnology" industry.

How does Helix BioPharma compare to Fennec Pharmaceuticals?

Helix BioPharma (TSE:HBP) and Fennec Pharmaceuticals (TSE:FRX) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, valuation, media sentiment, analyst recommendations, dividends, earnings, institutional ownership and profitability.

Helix BioPharma has a net margin of 0.00% compared to Fennec Pharmaceuticals' net margin of -17.22%. Helix BioPharma's return on equity of -36.79% beat Fennec Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Helix BioPharmaN/A -36.79% -279.98%
Fennec Pharmaceuticals -17.22%-58.09%8.88%

Fennec Pharmaceuticals has higher revenue and earnings than Helix BioPharma. Fennec Pharmaceuticals is trading at a lower price-to-earnings ratio than Helix BioPharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Helix BioPharmaN/AN/A-C$50.55M-C$0.06N/A
Fennec PharmaceuticalsC$51.00M8.45-C$800.44K-C$0.29N/A

Helix BioPharma has a beta of 0.421776, suggesting that its share price is 58% less volatile than the broader market. Comparatively, Fennec Pharmaceuticals has a beta of 3.518081, suggesting that its share price is 252% more volatile than the broader market.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Helix BioPharma
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Fennec Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
1 Strong Buy rating(s)
4.00

In the previous week, Fennec Pharmaceuticals had 3 more articles in the media than Helix BioPharma. MarketBeat recorded 4 mentions for Fennec Pharmaceuticals and 1 mentions for Helix BioPharma. Helix BioPharma's average media sentiment score of 1.08 beat Fennec Pharmaceuticals' score of 0.20 indicating that Helix BioPharma is being referred to more favorably in the media.

Company Overall Sentiment
Helix BioPharma Positive
Fennec Pharmaceuticals Neutral

0.0% of Helix BioPharma shares are held by institutional investors. Comparatively, 12.7% of Fennec Pharmaceuticals shares are held by institutional investors. 2.2% of Helix BioPharma shares are held by company insiders. Comparatively, 16.2% of Fennec Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Fennec Pharmaceuticals beats Helix BioPharma on 9 of the 14 factors compared between the two stocks.

How does Helix BioPharma compare to ProMetic Life Sciences?

Helix BioPharma (TSE:HBP) and ProMetic Life Sciences (TSE:PLI) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, media sentiment, risk, valuation, dividends, profitability and analyst recommendations.

0.0% of Helix BioPharma shares are owned by institutional investors. 2.2% of Helix BioPharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Helix BioPharma has higher earnings, but lower revenue than ProMetic Life Sciences. Helix BioPharma is trading at a lower price-to-earnings ratio than ProMetic Life Sciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Helix BioPharmaN/AN/A-C$50.55M-C$0.06N/A
ProMetic Life SciencesC$39.91M0.00-C$1.47B-C$63.06N/A

In the previous week, Helix BioPharma had 1 more articles in the media than ProMetic Life Sciences. MarketBeat recorded 1 mentions for Helix BioPharma and 0 mentions for ProMetic Life Sciences. Helix BioPharma's average media sentiment score of 1.08 beat ProMetic Life Sciences' score of 0.00 indicating that Helix BioPharma is being referred to more favorably in the media.

Company Overall Sentiment
Helix BioPharma Positive
ProMetic Life Sciences Neutral

ProMetic Life Sciences' return on equity of 0.00% beat Helix BioPharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Helix BioPharmaN/A -36.79% -279.98%
ProMetic Life Sciences N/A N/A N/A

Summary

Helix BioPharma beats ProMetic Life Sciences on 6 of the 10 factors compared between the two stocks.

How does Helix BioPharma compare to VIVO Cannabis?

Helix BioPharma (TSE:HBP) and VIVO Cannabis (CVE:ABCN) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, dividends, earnings, institutional ownership, risk, profitability, valuation and analyst recommendations.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Helix BioPharmaN/AN/A-C$50.55M-C$0.06N/A
VIVO CannabisN/AN/AN/AN/AN/A

In the previous week, Helix BioPharma had 1 more articles in the media than VIVO Cannabis. MarketBeat recorded 1 mentions for Helix BioPharma and 0 mentions for VIVO Cannabis. Helix BioPharma's average media sentiment score of 1.08 beat VIVO Cannabis' score of 0.00 indicating that Helix BioPharma is being referred to more favorably in the media.

Company Overall Sentiment
Helix BioPharma Positive
VIVO Cannabis Neutral

0.0% of Helix BioPharma shares are held by institutional investors. 2.2% of Helix BioPharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

VIVO Cannabis' return on equity of 0.00% beat Helix BioPharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Helix BioPharmaN/A -36.79% -279.98%
VIVO Cannabis N/A N/A N/A

Summary

Helix BioPharma beats VIVO Cannabis on 4 of the 6 factors compared between the two stocks.

How does Helix BioPharma compare to Emblem?

Helix BioPharma (TSE:HBP) and Emblem (CVE:EMC) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, dividends, profitability, earnings, risk, analyst recommendations, media sentiment and institutional ownership.

Emblem's return on equity of 0.00% beat Helix BioPharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Helix BioPharmaN/A -36.79% -279.98%
Emblem N/A N/A N/A

0.0% of Helix BioPharma shares are held by institutional investors. 2.2% of Helix BioPharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Emblem has higher revenue and earnings than Helix BioPharma. Helix BioPharma is trading at a lower price-to-earnings ratio than Emblem, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Helix BioPharmaN/AN/A-C$50.55M-C$0.06N/A
Emblem$5.71M43.02-$24.81M-$0.19N/A

In the previous week, Helix BioPharma had 1 more articles in the media than Emblem. MarketBeat recorded 1 mentions for Helix BioPharma and 0 mentions for Emblem. Helix BioPharma's average media sentiment score of 1.08 beat Emblem's score of 0.00 indicating that Helix BioPharma is being referred to more favorably in the media.

Company Overall Sentiment
Helix BioPharma Positive
Emblem Neutral

Summary

Helix BioPharma and Emblem tied by winning 5 of the 10 factors compared between the two stocks.

How does Helix BioPharma compare to Theratechnologies?

Helix BioPharma (TSE:HBP) and Theratechnologies (TSE:TH) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, risk, media sentiment, dividends, institutional ownership, analyst recommendations, earnings and valuation.

In the previous week, Helix BioPharma had 1 more articles in the media than Theratechnologies. MarketBeat recorded 1 mentions for Helix BioPharma and 0 mentions for Theratechnologies. Helix BioPharma's average media sentiment score of 1.08 beat Theratechnologies' score of 0.00 indicating that Helix BioPharma is being referred to more favorably in the media.

Company Overall Sentiment
Helix BioPharma Positive
Theratechnologies Neutral

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Helix BioPharma
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Theratechnologies
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00

Theratechnologies has higher revenue and earnings than Helix BioPharma. Helix BioPharma is trading at a lower price-to-earnings ratio than Theratechnologies, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Helix BioPharmaN/AN/A-C$50.55M-C$0.06N/A
TheratechnologiesC$84.38M2.44-C$1.96M-C$0.19N/A

Helix BioPharma has a net margin of 0.00% compared to Theratechnologies' net margin of -11.81%. Theratechnologies' return on equity of 16.59% beat Helix BioPharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Helix BioPharmaN/A -36.79% -279.98%
Theratechnologies -11.81%16.59%5.15%

Helix BioPharma has a beta of 0.421776, indicating that its stock price is 58% less volatile than the broader market. Comparatively, Theratechnologies has a beta of 0.256166, indicating that its stock price is 74% less volatile than the broader market.

0.0% of Helix BioPharma shares are held by institutional investors. Comparatively, 0.5% of Theratechnologies shares are held by institutional investors. 2.2% of Helix BioPharma shares are held by insiders. Comparatively, 1.2% of Theratechnologies shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Theratechnologies beats Helix BioPharma on 7 of the 13 factors compared between the two stocks.

Get Helix BioPharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for HBP and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

HBP vs. The Competition

Export
MetricHelix BioPharmaBiotechnology IndustryMedical SectorTSE Exchange
Market CapC$120.68MC$445.63MC$6.52BC$12.19B
Dividend Yield1.50%3.88%2.67%6.19%
P/E Ratio-26.333.1924.0036.94
Price / SalesN/A6,464.11514.3610.45
Price / Cash11.3213.1327.4882.29
Price / Book7.8686.7510.544.47
Net Income-C$50.55M-C$96.07MC$3.57BC$299.09M
7 Day Performance3.27%0.09%0.60%0.65%
1 Month PerformanceN/A-0.27%1.56%-0.08%
1 Year PerformanceN/A56.11%25.42%41.90%

Helix BioPharma Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
HBP
Helix BioPharma
N/AC$1.58
flat		N/AN/AC$120.68MN/AN/A9
FRX
Fennec Pharmaceuticals
0.1563 of 5 stars		C$12.44
flat		N/AN/AC$432.13MC$51.00MN/A10
PLI
ProMetic Life Sciences
N/AN/AN/AN/AC$317.06MC$39.91MN/A487
ABCN
VIVO Cannabis
N/AC$1.32
+5.6%		N/A+0.0%C$256.62MN/AN/AN/A
EMC
Emblem
N/A$1.88
+1.6%		N/A+0.0%$245.45M$5.71MN/AN/A

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (TSE:HBP) was last updated on 6/15/2026 by MarketBeat.com Staff.
From Our Partners
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Is SpaceX really worth 1.78 Trillion?
With SpaceX approaching a near-$2 trillion valuation, most investors are focused on the IPO itself - but analy...
InvestPub | Sponsoredtc pixel
Hey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...
After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...
Banyan Hill Publishing | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
SpaceX is chump change compared to Elon’s $20T ‘iPhone’
Early Apple investors saw peak gains as high as 7,537% after the iPhone launched. Now, multiple insider source...
StocksToTrade | Sponsoredtc pixel
The roadshow starts Monday. This stock isn't ready.
The SpaceX roadshow kicks off June 8. Goldman Sachs, the lead underwriter, will present the full S-1 to the wo...
Behind the Markets | Sponsoredtc pixel
Trump just signed it
A recent policy development is drawing attention from income-focused investors. According to one analyst, c...
Investors Alley | Sponsoredtc pixel